Literature DB >> 12050378

Regulation of DNA-raised immune responses by cotransfected interferon regulatory factors.

Shin Sasaki1, Rama Rao Amara, Wen-Shuz Yeow, Paula M Pitha, Harriet L Robinson.   

Abstract

Interferon regulatory factor 1 (IRF-1), IRF-3, and IRF-7 have been tested as genetic adjuvants for influenza virus hemagglutinin (HA) and nucleoprotein vaccine DNAs. Cotransfection of HA with IRF-3 and IRF-7 increased CD4 T-cell responses by 2- to 4-fold and CD8 T-cell responses by more than 10-fold. Following intramuscular deliveries of DNA, both CD4 and CD8 T cells were biased towards type 1 immune responses and the production of gamma interferon. Following gene gun bombardments of DNA, both were biased towards type 2 immune responses and the production of interleukin-4. The biases of the T-cell responses towards type 1 or type 2 were stronger for immunizations with IRF-3 as an adjuvant than for immunizations with IRF-7 as an adjuvant. Moderate adjuvant effects for antibody were observed. The isotypes of the antibody responses reflected the method of DNA delivery; intramuscular deliveries of DNA predominantly raised immunoglobulin G2a (IgG2a), whereas gene gun deliveries of DNA predominantly raised IgG1. These biases were enhanced by the codelivered IRFs. Overall, under the conditions of our experiments, IRF-3 had good activity for T cells, IRF-7 had good activity for both antibody and T cells, and IRF-1 had good activity for antibody.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12050378      PMCID: PMC136278          DOI: 10.1128/jvi.76.13.6652-6659.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  Type I IFNs enhance the terminal differentiation of dendritic cells.

Authors:  T Luft; K C Pang; E Thomas; P Hertzog; D N Hart; J Trapani; J Cebon
Journal:  J Immunol       Date:  1998-08-15       Impact factor: 5.422

Review 2.  Modulating the immune response to genetic immunization.

Authors:  A D Cohen; J D Boyer; D B Weiner
Journal:  FASEB J       Date:  1998-12       Impact factor: 5.191

Review 3.  The growing family of interferon regulatory factors.

Authors:  H Nguyen; J Hiscott; P M Pitha
Journal:  Cytokine Growth Factor Rev       Date:  1997-12       Impact factor: 7.638

4.  Direct triggering of the type I interferon system by virus infection: activation of a transcription factor complex containing IRF-3 and CBP/p300.

Authors:  M Yoneyama; W Suhara; Y Fukuhara; M Fukuda; E Nishida; T Fujita
Journal:  EMBO J       Date:  1998-02-16       Impact factor: 11.598

5.  Interferon regulatory factor 3 and CREB-binding protein/p300 are subunits of double-stranded RNA-activated transcription factor DRAF1.

Authors:  B K Weaver; K P Kumar; N C Reich
Journal:  Mol Cell Biol       Date:  1998-03       Impact factor: 4.272

6.  Differential viral induction of distinct interferon-alpha genes by positive feedback through interferon regulatory factor-7.

Authors:  I Marié; J E Durbin; D E Levy
Journal:  EMBO J       Date:  1998-11-16       Impact factor: 11.598

7.  Primary activation of interferon A and interferon B gene transcription by interferon regulatory factor 3.

Authors:  Y T Juang; W Lowther; M Kellum; W C Au; R Lin; J Hiscott; P M Pitha
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

8.  Characterization of the interferon regulatory factor-7 and its potential role in the transcription activation of interferon A genes.

Authors:  W C Au; P A Moore; D W LaFleur; B Tombal; P M Pitha
Journal:  J Biol Chem       Date:  1998-10-30       Impact factor: 5.157

9.  Virus infection induces the assembly of coordinately activated transcription factors on the IFN-beta enhancer in vivo.

Authors:  M G Wathelet; C H Lin; B S Parekh; L V Ronco; P M Howley; T Maniatis
Journal:  Mol Cell       Date:  1998-03       Impact factor: 17.970

10.  Type I interferons keep activated T cells alive.

Authors:  P Marrack; J Kappler; T Mitchell
Journal:  J Exp Med       Date:  1999-02-01       Impact factor: 14.307

View more
  25 in total

1.  Unexpected similarities in cellular responses to bacterial and viral invasion.

Authors:  Paula M Pitha
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-12       Impact factor: 11.205

2.  Coexpressed RIG-I agonist enhances humoral immune response to influenza virus DNA vaccine.

Authors:  Jeremy M Luke; Gregory G Simon; Jonas Söderholm; John S Errett; J Thomas August; Michael Gale; Clague P Hodgson; James A Williams
Journal:  J Virol       Date:  2010-11-24       Impact factor: 5.103

3.  Evidence for a DC-specific inhibitory mechanism that depends on MyD88 and SIGIRR.

Authors:  S K Drexler; J Wales; E Andreakos; P Kong; A Davis; C Garlanda; A Mantovani; T Hussell; M Feldmann; B M J Foxwell
Journal:  Scand J Immunol       Date:  2010-06       Impact factor: 3.487

4.  Biomaterials at the interface of nano- and micro-scale vector-cellular interactions in genetic vaccine design.

Authors:  Charles H Jones; Anders P Hakansson; Blaine A Pfeifer
Journal:  J Mater Chem B       Date:  2014-09-12       Impact factor: 6.331

Review 5.  DNA vaccines for prostate cancer.

Authors:  Christopher D Zahm; Viswa Teja Colluru; Douglas G McNeel
Journal:  Pharmacol Ther       Date:  2017-02-07       Impact factor: 12.310

6.  RNA-dependent protein kinase is required for alpha-1 interferon transgene-induced resistance to genital herpes simplex virus type 2.

Authors:  Daniel J J Carr; Lisa Tomanek; Robert H Silverman; Iain L Campbell; Bryan R G Williams
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

7.  Mucosal co-immunization with AIM2 enhances protective SIgA response and increases prophylactic efficacy of chitosan-DNA vaccine against coxsackievirus B3-induced myocarditis.

Authors:  Dafei Chai; Yan Yue; Wei Xu; Chunsheng Dong; Sidong Xiong
Journal:  Hum Vaccin Immunother       Date:  2014-03-10       Impact factor: 3.452

8.  DAI (DLM-1/ZBP1) as a genetic adjuvant for DNA vaccines that promotes effective antitumor CTL immunity.

Authors:  Alvaro Lladser; Dimitrios Mougiakakos; Helena Tufvesson; Maarten A Ligtenberg; Andrew Fg Quest; Rolf Kiessling; Karl Ljungberg
Journal:  Mol Ther       Date:  2010-12-14       Impact factor: 11.454

9.  Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors.

Authors:  Andrea Worschech; Maciej Kmieciak; Keith L Knutson; Harry D Bear; Aladar A Szalay; Ena Wang; Francesco M Marincola; Masoud H Manjili
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

10.  Intracellular HIV-1 Tat protein represses constitutive LMP2 transcription increasing proteasome activity by interfering with the binding of IRF-1 to STAT1.

Authors:  Anna L Remoli; Giulia Marsili; Edvige Perrotti; Eleonora Gallerani; Ramona Ilari; Filomena Nappi; Aurelio Cafaro; Barbara Ensoli; Riccardo Gavioli; Angela Battistini
Journal:  Biochem J       Date:  2006-06-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.